{
  "success": true,
  "sourceFile": ".\\input\\trial\\NCT03730662_SURPASS4\\NCT03730662_SURPASS4_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Screened population",
        "text": "All participants who sign informed consent",
        "populationType": "Other",
        "instanceType": "AnalysisPopulation",
        "label": "Screened",
        "populationDescription": "All participants who sign informed consent",
        "criteria": "Signed informed consent"
      },
      {
        "id": "pop_2",
        "name": "Randomized population",
        "text": "All patients who are randomly assigned a treatment arm",
        "populationType": "Other",
        "instanceType": "AnalysisPopulation",
        "label": "Randomized",
        "populationDescription": "All patients who are randomly assigned a treatment arm",
        "criteria": "Randomly assigned a treatment arm"
      },
      {
        "id": "pop_3",
        "name": "Modified intent-to-treat population",
        "text": "All randomly assigned participants who are exposed to at least 1 dose of study drug.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "mITT",
        "populationDescription": "All randomly assigned participants who are exposed to at least 1 dose of study drug.",
        "criteria": "Randomized AND received >=1 dose of study drug"
      },
      {
        "id": "pop_4",
        "name": "Efficacy analysis set",
        "text": "Data obtained during Study Period II and III from mITT, excluding patients discontinuing study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication or discontinuation of study drug (last dose date + 7 days).",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "EAS",
        "populationDescription": "Data obtained during Study Period II and III from mITT, excluding patients discontinuing study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication or discontinuation of study drug (last dose date + 7 days).",
        "criteria": "mITT AND not discontinued due to inadvertent enrollment AND data prior to rescue/discontinuation"
      },
      {
        "id": "pop_5",
        "name": "Full analysis set",
        "text": "Data obtained during Study Period II and III from mITT, excluding patients discontinuing study drug due to inadvertent enrollment, regardless of adherence to study drug or initiation of rescue antihyperglycemic medication.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS",
        "populationDescription": "Data obtained during Study Period II and III from mITT, excluding patients discontinuing study drug due to inadvertent enrollment, regardless of adherence to study drug or initiation of rescue antihyperglycemic medication.",
        "criteria": "mITT AND not discontinued due to inadvertent enrollment"
      },
      {
        "id": "pop_6",
        "name": "Safety analysis set",
        "text": "Data obtained during Study Period II, III, and IV from mITT, regardless of adherence to study drug or initiation of new antihyperglycemic medication.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SS",
        "populationDescription": "Data obtained during Study Period II, III, and IV from mITT, regardless of adherence to study drug or initiation of new antihyperglycemic medication.",
        "criteria": "mITT"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "HbA1c",
        "code": "HBA1C",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "HbA1c",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Hemoglobin A1c concentration at baseline"
      },
      {
        "id": "char_2",
        "name": "SGLT-2i use",
        "code": "SGLT-2I_USE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "SGLT-2i use",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Baseline use of sodium-glucose co-transporter-2 inhibitor"
      },
      {
        "id": "char_3",
        "name": "Country",
        "code": "COUNTRY",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Country",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Country of the participant"
      }
    ],
    "summary": {
      "populationCount": 6,
      "characteristicCount": 3
    }
  }
}